Navigation Links
Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:1/12/2009

ver-targeting technology. This technology enables the delivery of high levels of nucleoside triphosphate in the liver, potentially maximizing drug efficacy and limiting systemic side effects. In HCV genotype-1 infected chimpanzees, once-daily oral administration of 10 mg/kg/day of IDX184 produced a mean viral load reduction of 2.3 log10 after four days of dosing. In a phase I study in healthy volunteers evaluating doses ranging from 5 to 100 mg/day, IDX184 was safe and well-tolerated; the most common adverse event reported in this study was dizziness and it was more frequently reported in subjects receiving placebo.

2008 Financial Guidance

Idenix today reported that it ended 2008 with approximately $46 million of cash, cash equivalents and marketable securities, within the range of the company's prior cash guidance. The company's 2008 financial results have not yet been audited.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other

infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "may," "plans," "anticipates," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any other potential pipeline candidate. Such forward-looking statements in
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
2. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... COLORADO SPRINGS, Colo. , July 31, 2014 ... Company specializing in cannabis formulation-based drug development and ... has commenced production of multiple strains of cannabis ... scientific research to select the best strains for ... to bring the cannabis formulations to market for ...
(Date:7/31/2014)... Texas , July 31, 2014 Vermillion, Inc. ... and women,s health, will hold a conference call on Thursday, ... results for the second quarter ended June 30, 2014. Financial ... the call. Vermillion,s Chairman, President and CEO ... question and answer period. Date: Thursday, August 14, ...
(Date:7/31/2014)... , July 31, 2014  Today, ... a new extension to its PageCenterX ® ... software is designed to provide downtime reporting capabilities ... outages. LRS is releasing the product for general ... environment, EMR applications experience outages for a variety ...
Breaking Medicine Technology:Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2LRS Announces Downtime Reporting Solution for Healthcare 2
... SEATTLE, WA, Nov. 13 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation and disorders of ... hold a conference call on Thursday, November 19, 2009 ... provide a corporate update. Gregory A. Demopulos, M.D., Chairman ...
... EDDA Technology today announced the completion of ... an advanced clinical application designed to enhance efficiency ... planning. , IQQA®-Liver provides a comprehensive toolset ... liver lobes and segments, hepatic lesions, and vascular ...
Cached Medicine Technology:Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19 2EDDA Technology Completes CE Mark for IQQA(R)-Liver for Fast Quantitative Volumetry Assessment from Liver MDCT 2EDDA Technology Completes CE Mark for IQQA(R)-Liver for Fast Quantitative Volumetry Assessment from Liver MDCT 3
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, “It ... newly released article entitled, “ 5 Signs That Your ... ,” Clean Crawls explains the need to replace insulation ... critters. , Get a free attic insulation or ... http://www.cleancrawl.com/contact . , If crawl space or attic insulation ...
(Date:8/1/2014)... 2014 Over 20,000 entrepreneurs from around ... 2014 Market America | SHOP.COM International Convention at the ... annual event will introduce new products, technology, programs and ... and also feature a who’s who of celebrities. ... SHOP.COM Executive Team, successful entrepreneurs and celebrity guests. Previous ...
(Date:8/1/2014)... CA (PRWEB) August 01, 2014 ... advancing gynecologic endoscopic surgery, is pleased to announce ... in the United States and Europe, which strongly ... available to surgeons an endoscopic dry lab for ... of their endoscopic surgery skills. , Endoscopy is ...
(Date:8/1/2014)... 01, 2014 Stress management can be difficult ... hours of concentration and diminish rest and leisure time, stress ... is critical to find a way to manage stress in ... life. , “Having a good sense of work-life balance is ... Jacobs, founding clinician of SF Custom Chiropractic. “Stress, left ...
(Date:7/31/2014)... July 31, 2014 The 2013 ... developments about chemical listings, appellate decisions, litigation and ... may affect compliance with California's Proposition 65. , ... the law, regulations, history and trends impacting California's ... fourth installment of the series which adds approximately ...
Breaking Medicine News(10 mins):Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 3Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 4Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 5Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2
... marketing is a missed opportunity for states to improve ... alcohol advertising laws from the Center on Alcohol Marketing ... of Public Health. The report examines the ... different best practices to reduce youth exposure to alcohol ...
... of an important clinical trial on age-related macular degeneration ... (or CATT), were published in the journal Ophthalmology ... Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat ... maintaining vision. In this clinical trial ...
... -- A management plan to gather, assess and respond to ... approved until they are no longer on the market is ... an Institute of Medicine report released Tuesday. The U.S. ... trial evidence that their benefits outweigh their risks. However, the ...
... MONDAY, April 30 (HealthDay News) -- A new analysis ... says those with a family history of breast cancer or ... The benefits of getting a mammogram every two years ... increased risk for developing breast cancer, according to the U.S. ...
... 1 (HealthDay News) -- Taser guns used by law enforcement ... according to a new study. Tasers, which are widely ... countries, are designed to stun suspects by delivering a 50,000-volt ... analyzed the cases of eight healthy men, ages 16 to ...
... for ordering chest CT examinations translates into positive examinations ... The study, conducted at Massachusetts General Hospital in Boston, ... of a decision support system, found that 76% of ... , "Rising concerns about radiation risks, imaging growth and ...
Cached Medicine News:Health News:Majority of states fail to address youth exposure to alcohol marketing 2Health News:Interpreting the Avastin-Lucentis study for persons with macular degeneration 2Health News:Interpreting the Avastin-Lucentis study for persons with macular degeneration 3Health News:Better Ways Needed to Track Drug Safety: Report 2Health News:Better Ways Needed to Track Drug Safety: Report 3Health News:Here Are the Women Who Need Mammograms in Their 40s: Study 2Health News:Here Are the Women Who Need Mammograms in Their 40s: Study 3
Smartepil II is a laser particularly indicated for hair-removal where it has proved to be a valid instrument, even in the treatment of darker phototypes and telangiectasias of the face and legs....
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... is a CO2 laser system with ... Its functions in continuous and super-pulsed ... extreme laser intervention delicacy. Excellent as ... it comes with a large LCD ...
... professional digital imaging system for ophthalmology and ... to acquire, analyze, and store your patient ... use the most are,available right on the ... easily. This high-resolution system supports images captured ...
Medicine Products: